In This Article:
A new report from AARP Public Policy Institute found that the top 25 drugs prescribed under Medicare Part D have nearly doubled in price since market entry, exceeding inflation trends.
Yahoo Finance senior health reporter Anjalee Khemlani joins Brad Smith on Wealth to discuss the findings, highlighting significant cost increases for key medications, including Merck's (MRK) diabetes drug Janumet, soaring nearly 300% in its lifetime on the market dating back to 2007.
While Medicare is beginning to negotiate prices, GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Ozempic are already seeing price increases since their debuts.
To watch more expert insights and analysis on the latest market action, check out more Wealth! here.
This post was written by Josh Lynch